Evidence map›Paper›PMID 36291953›Full record

ReviewCancers2022

"Intestinal-Type" Vulvar Adenocarcinoma: A Review of the MITO Rare Tumors Group.

Miriam Dellino, Stefania Cicogna, Francesca Falcone, Marco Mitidieri, Roberta Mazzeo, Sandro Pignata, Giorgia Mangili, Gennaro Cormio

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 1 country.

Miriam DellinoDepartment of Biomedical Sciences and Human Oncology, University of Bari, 70100 Bari, Italy.ORCID 0000-0003-3522-4648
Stefania CicognaDepartment of Obstetrics and Gynaecology, Institute for Maternal and Child Health-IRCCS "Burlo Garofolo", 34137 Trieste, Italy.ORCID 0000-0002-7964-9675
Francesca FalconeDepartment of Gynecologic Oncology, Istituto Nazionale Tumori, IRCSS, "Fondazione G. Pascale", 80131 Naples, Italy.
Marco MitidieriAzienda Ospedaliero Universitaria Città della Scienza e della Salute di Torino, Ginecologia e Ostetricia SC4, 10126 Turin, Italy.
Roberta MazzeoDepartment of Medicine (DAME), University of Udine, 33100 Udine, Italy.
Sandro PignataDepartment of Urology and Gynecology, Istituto Nazionale Tumori, IRCSS, "Fondazione G. Pascale", 80131 Naples, Italy.ORCID 0000-0002-8836-2633
Giorgia MangiliObstetrics and Gynecology Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
Gennaro CormioGynecologic Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, Department of Interdisciplinary Medicine (DIM), University of Bari "Aldo Moro", 70121 Bari, Italy.ORCID 0000-0001-5745-372X
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITIRCCS Materno Infantile Burlo Garofolo · ITIstituto Tumori Bari · ITOspedale San Paolo · ITUniversity of Udine · ITVita-Salute San Raffaele University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intestinal-type adenocarcinoma (VAIt) represents a sporadic variant of vulvar carcinoma. It appears frequently localized to epithelial glands in the vulvar region, and it probably derives from cloacal remnants persisting in the adult. We performed a systematic review of the limited cases reported in the literature, with the intent to assess the specific peculiarities of this rare neoplasia and to state consistent management recommendations. The principal histological VAIt characteristic is that it resembles mucinous colonic carcinomas. Therefore, immunohistochemical workup, with different tumor markers including CK20, CDX2, and CK7 staining, is needed. To confirm vulvar origin, a thorough diagnostic, and radiological examination is required to rule out other primary malignancies. The gold standard of treatment for VAIt is surgery, with local excision with tumor-free margins. Lymph node staging is an option advised if the tumor size is >2 cm or if lymph node metastases are suspected on imaging. On the other hand, the role of neoadjuvant therapy is still in doubt, but a good response to adjuvant chemotherapy treatments has been described in both advanced and recurrent diseases. Sometimes, VAIt behavior can be unpredictable, with relapses even after many years, so more experiences and longer follow-up periods are needed to elucidate the best therapeutic management and its long-term prognosis.

Indexed as

adenocarcinomaintestinal typevulvar cancer

Identifiers

PMID36291953
PMCPMC9600239
OpenAlexW4307656948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.